Premium
Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma
Author(s) -
Kyrtsonis MarieChristine,
Vassilakopoulos Theodoros P.,
Kafasi Nicoletta,
Sachanas Sotirios,
Tzenou Tatiana,
Papadogiannis Argiroula,
Galanis Zacharoula,
Kalpadakis Christina,
Dimou Maria,
Kyriakou Elias,
Angelopoulou Maria K.,
Dimopoulou Maria N.,
Siakantaris Marina P.,
Dimitriadou Evangelia M.,
Kokoris Styliani I.,
Panayiotidis Panayiotis,
Pangalis Gerassimos A.
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06561.x
Subject(s) - multiple myeloma , immunoglobulin light chain , medicine , creatinine , gastroenterology , lactate dehydrogenase , pathology , oncology , immunology , antibody , chemistry , biochemistry , enzyme
Summary The prognostic value of baseline serum free light chain ratio (sFLCR) was investigated in 94 multiple myeloma (MM) patients. sFLCR was calculated as κ / λ or λ / κ , depending on the patients’ dominating monoclonal light chain. Median baseline sFLCR was 3·57 in κ ‐MM patients, 45·09 in λ ‐MM. ‘High’ sFLCR (≥ the observed median value for κ ‐ and λ ‐MM respectively) correlated with elevated serum creatinine and lactate dehydrogenase, extensive marrow infiltration and light chain type MM. The 5‐year disease‐specific survival was 82% and 30% in patients with sFLCR lower than and equal or greater than the median, respectively ( P = 0·0001). sFLCR was an independent prognostic factor.